MSC Secretome Therapy for Cognitive Recovery After Subacute Ischemic Stroke

Inclusion Criteria: 1. Age 40 to 75 years. 2. Diagnosis of ischemic stroke confirmed by clinical examination and computed tomography or magnetic resonance imaging. 3. Stroke onset between 7 days and 3 months before enrollment. 4. Hemodynamically stable. 5. Able to undergo a basic neuropsychological assessment. 6. Mild-to-moderate cognitive impairment based on the Indonesian version of the Montreal Cognitive Assessment. 7. Willing to participate in the study and provide written informed consent. Exclusion Criteria: 1. Hemorrhagic stroke or mixed ischemic and hemorrhagic stroke. 2. Severe aphasia, impaired consciousness, or severe sensory deficits that make cognitive assessment invalid. 3. History of dementia before stroke or a major neurodegenerative disorder. 4. Active infection, active autoimmune disease, active malignancy, severe renal failure, or severe liver failure. 5. Uncontrolled epilepsy. 6. Concurrent participation in another clinical trial. 7. Contraindication to any study intervention or study procedure.